Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1978 1
1980 2
1981 4
1982 2
1983 4
1984 9
1985 12
1986 8
1987 13
1988 19
1989 21
1990 24
1991 25
1992 31
1993 36
1994 32
1995 39
1996 67
1997 43
1998 56
1999 53
2000 45
2001 67
2002 71
2003 71
2004 85
2005 102
2006 113
2007 103
2008 123
2009 117
2010 142
2011 135
2012 153
2013 178
2014 177
2015 205
2016 198
2017 185
2018 234
2019 242
2020 258
2021 268
2022 239
2023 209
2024 91

Text availability

Article attribute

Article type

Publication date

Search Results

3,846 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "ALG3-congenital disorder of glycosylation"
Page 1
N-Glycosylation and Inflammation; the Not-So-Sweet Relation.
Radovani B, Gudelj I. Radovani B, et al. Front Immunol. 2022 Jun 27;13:893365. doi: 10.3389/fimmu.2022.893365. eCollection 2022. Front Immunol. 2022. PMID: 35833138 Free PMC article. Review.
Chronic inflammation is the main feature of many long-term inflammatory diseases such as autoimmune diseases, metabolic disorders, and cancer. There is a growing number of studies in which alterations of N-glycosylation have been observed in many pathophysiol …
Chronic inflammation is the main feature of many long-term inflammatory diseases such as autoimmune diseases, metabolic disorders, an …
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Luo G, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19. Biochim Biophys Acta Rev Cancer. 2021. PMID: 32827580 Review.
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. ...CA19-9 has screening potential when combined with sy …
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. C …
Glycosylation and Cardiovascular Diseases.
Dashti H, Pabon Porras MA, Mora S. Dashti H, et al. Adv Exp Med Biol. 2021;1325:307-319. doi: 10.1007/978-3-030-70115-4_15. Adv Exp Med Biol. 2021. PMID: 34495542
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 18 million deaths in 2017. Coronary artery disease is the predominant cause of death from CVD, followed by stroke. ...
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 18 million deaths in 2017. Coronar …
Gain-of-glycosylation mutations.
Vogt G, Vogt B, Chuzhanova N, Julenius K, Cooper DN, Casanova JL. Vogt G, et al. Curr Opin Genet Dev. 2007 Jun;17(3):245-51. doi: 10.1016/j.gde.2007.04.008. Epub 2007 Apr 30. Curr Opin Genet Dev. 2007. PMID: 17467977 Review.
A pathogenic mechanism involves the addition of a novel N-linked glycan. Up to 1.4% of known disease-causing missense mutations are predicted to give rise to gains-of-glycosylation. ...The chemical complementation of cells from patients in vitro with various …
A pathogenic mechanism involves the addition of a novel N-linked glycan. Up to 1.4% of known disease-causing missense mutations are …
Glycosylation changes in inflammatory diseases.
Groux-Degroote S, Cavdarli S, Uchimura K, Allain F, Delannoy P. Groux-Degroote S, et al. Adv Protein Chem Struct Biol. 2020;119:111-156. doi: 10.1016/bs.apcsb.2019.08.008. Epub 2019 Nov 26. Adv Protein Chem Struct Biol. 2020. PMID: 31997767 Review.
Alterations of glycosylation are observed in a number of inflammatory diseases. Pro-inflammatory cytokines have been shown to modulate cell surface glycosylation by regulating the expression of glycosyltransferases and sulfotransferases involved in the biosyn …
Alterations of glycosylation are observed in a number of inflammatory diseases. Pro-inflammatory cytokines have been shown to …
Congenital disorders of glycosylation and infantile epilepsy.
Lee HF, Chi CS. Lee HF, et al. Epilepsy Behav. 2023 May;142:109214. doi: 10.1016/j.yebeh.2023.109214. Epub 2023 Apr 21. Epilepsy Behav. 2023. PMID: 37086590 Review.
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in various defects of protein or lipid glycosylation pathways. The symptoms and signs of CDG usually develop in infancy. Epilepsy is commonl …
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in vari …
Inflammatory bowel disease - glycomics perspective.
Hanić M, Trbojević-Akmačić I, Lauc G. Hanić M, et al. Biochim Biophys Acta Gen Subj. 2019 Oct;1863(10):1595-1601. doi: 10.1016/j.bbagen.2019.07.001. Epub 2019 Jul 2. Biochim Biophys Acta Gen Subj. 2019. PMID: 31276732 Review.
Glycosylation has shown a promising biomarker potential for early IBD diagnosis and effective response to treatment prediction. SCOPE OF REVIEW: This mini-review briefly covers present knowledge of IBD pathophysiology, with a focus on recent research on the role of …
Glycosylation has shown a promising biomarker potential for early IBD diagnosis and effective response to treatment prediction …
Mucin-Type O-Glycosylation in Gastric Carcinogenesis.
Duarte HO, Freitas D, Gomes C, Gomes J, Magalhães A, Reis CA. Duarte HO, et al. Biomolecules. 2016 Jul 11;6(3):33. doi: 10.3390/biom6030033. Biomolecules. 2016. PMID: 27409642 Free PMC article. Review.
Mucin-type O-glycosylation plays a crucial role in several physiological and pathological processes of the gastric tissue. Modifications in enzymes responsible for key glycosylation steps and the consequent abnormal biosynthesis and expression of their glycan produc …
Mucin-type O-glycosylation plays a crucial role in several physiological and pathological processes of the gastric tissue. Modificati …
Artificial intelligence in the analysis of glycosylation data.
Li H, Chiang AWT, Lewis NE. Li H, et al. Biotechnol Adv. 2022 Nov;60:108008. doi: 10.1016/j.biotechadv.2022.108008. Epub 2022 Jun 20. Biotechnol Adv. 2022. PMID: 35738510 Review.
They are involved in diverse essential organismal functions. Aberrant glycosylation may lead to disease development, such as cancer, autoimmune diseases, and inflammatory diseases. ...Finally, we propose how to leverage the gained knowledge for developing predict …
They are involved in diverse essential organismal functions. Aberrant glycosylation may lead to disease development, such as c …
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN, Radenkovic S, Saraswat M, Garapati K, Ranatunga W, Krzysciak W, Yanaihara H, Preston G, Brucker W, McGovern RM, Reid JM, Cassiman D, Muthusamy K, Johnsen C, Mercimek-Andrews S, Larson A, Lam C, Edmondson AC, Ghesquière B, Witters P, Raymond K, Oglesbee D, Pandey A, Perlstein EO, Kozicz T, Morava E. Ligezka AN, et al. Ann Neurol. 2021 Dec;90(6):887-900. doi: 10.1002/ana.26245. Epub 2021 Oct 26. Ann Neurol. 2021. PMID: 34652821 Free PMC article.
OBJECTIVE: Epalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2-congenital disorders of glycosylation (CDG) worm model. Epalrestat also decreases sorbitol level in diabetic neuropathy. ...Compared with controls, 24% …
OBJECTIVE: Epalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2-congenital disorders …
3,846 results